Buccal absorption of enalapril and lisinopril

European Journal of Clinical Pharmacology

Volumn 54, Issue 8, 1998, Pages 609-614

  McElnay, J C ^a   Al Furaih, T A ^a   Hughes, C M ^a   Scott, M G ^a   Elborn, J S ^b   Nicholls, D P ^c  

^a QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

^b BELFAST CITY HOSPITAL   (United Kingdom)

^c ROYAL VICTORIA HOSPITAL   (United Kingdom)

Author keywords

Buccal absorption; Enalapril; Lisinopril

Indexed keywords

CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; LISINOPRIL;

ARTICLE; BUCCAL DRUG ADMINISTRATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG ABSORPTION; DRUG DETERMINATION; DRUG EFFECT; HUMAN; NORMAL HUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

ADMINISTRATION, BUCCAL; ADULT; CROSS-OVER STUDIES; ENALAPRIL; HUMANS; HYDROGEN-ION CONCENTRATION; LISINOPRIL; MALE; MOUTH; OCTANOLS; SINGLE-BLIND METHOD;

EID: 0031795948     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002280050522     Document Type: Article

References (20)

1. Beckett AH, Triggs EJ (1967) Buccal absorption of basic drugs and its application as an in vivo model of passive drug transfer through lipid membranes. J Pharm Pharmaeol 19 [Suppl]: 31S 41S
2. Beermann B, Gomez H, Till A, Junggren IL (1986). Pharmacokinetics of lisinopril in healthy volunteers. Ada Pharmacol Toxicol [Suppl V] 49: 66
3. Florence AT, Attwood D (1987) Physicochemical principles of pharmacy. MacMillan Education, London, pp 158-160
4. Friedman DI, Amidon GL (1989a) Passive and carrier-mediated intestinal absorption components of two angiotensin converting enzyme inhibitor prodrugs in rats: enalapril and fosinopril. Pharm Res 6: 1043-1047
5. Friedman DI, Amidon GL (1989b) Intestinal absorption mechanism of dipeptide angiotensin converting enzyme inhibitors of the lysyl-proline type: lisinopril and SQ29, 852. J Pharm Sci 78: 995-998
6. Haycock KA, Roth J, Gagnon J, Finzer WF, Soper C (1992) Statview. The ultimate integrated data analysis and presentation system. Abacus Concepts, Berkeley, pp 322-323
7. Hu M, Amidon GL (1988) Passive and carrier-mediated intestinal absorption components of captopril. J Pharm Sci 77: 1007-1011
8. Irvin JD, Till AE, Vlasses PH, Hichens M, Rotmensch HH, Harris KE, Merrill DD, Ferguson RK (1984) Bioavailability of enalapril maleate. Clin Pharmaeol Ther 35: 248
9. Kirschbaum J, Perlman S (1984) Analysis of captopril and hydrochlorothiazide combination tablet formulations by liquid chromatography. J Pharm Sci 73: 686-687
10. McElnay JC, Temple DJ (1982) The use of buccal partitioning as a model to examine the effects of aluminium hydroxide gel on the absorption of propranolol. Br J Clin Pharmaeol 13: 399-403
11. McElnay JC, Al-Furaih TA, Hughes CM, Scott MG, Elborn J, Nicholls DP (1995) The effect of pH on the buccal and sub-lingual absorption of captopril in healthy volunteers. Eur J Clin Pharmacol 48: 373-379
12. Mojaverian P, Rocci ML, Vlasses PH, Hoholick C, Clementi RA, Ferguson RK (1986) Effect of food on the bioavailability of lisinopril, a nonsulfhydryl angiotensin-converting enzyme inhibitor. J Pharm Sci 75: 395-397
13. Morrison RA, Chong S, Marino AM, Wassermann MA, Trimmins P, Moore VA, Irwin WJ (1996) Suitability of enalapril as a probe of the dipeptide transporter system: in vitro and in vivo studies. Pharm Res 13: 1078-1082
14. Pang KS, Cherry WF, Ulm EH (1985) Disposition of enalapril in the perfused rat intestine liver preparation: absorption. metabolism and first-pass elicet. J Pharmacol Exp Ther 233: 788-795
15. Runadive SA, Chen AX, Serajuddin AT (1992) Relative lipophilicities and structural-pharmacologieal considerations of various angiotensin-converting enzymc (ACE) inhibitors, Pharm Res 9: 1480-1486
16. Swanson BN, Vlasses PH, Ferguson RK, Bergquist PA, Till AH, Irvin JD, Harris K (1984) Influence of food on the bioavailability of enalapril. J Pharm Sci 73: 1655-1657
17. Thwaites DT, Cavet M, Hirst BH, Simmons NL (1995) Angiotensin-converting enzyme (ACE) inhibitor transport in human intestinal epithelial (Caco-2) cells. Br J Pharmacol 114: 981-986
18. Ulm EH (1983) Enalapril maleate (MK-421). A potent non-sulfhydryl angiotensin-converling enzyme inhibitor: absorption, disposition and metabolism in man. Drug Metab Rev 14: 99-110
19. Ulm EH, Hichens M, Gomez HJ, Hill AE, Hand E, Vassil TC, Biollaz J, Brunner HR, Sehelling J L (1982) Enalapril maleate and a lysine analogue (MK-521): disposition in man. Br J Clin Pharmacol 14: 357-362
20. Yuasa H, Amidon GL, Fleisher D (1993) Peptide carrier-mediated transport in intestinal brush border membrane vesicles of rats and rabbits: cephradine uptake and inhibition. Pharm Res 10: 400-404